Trilaciclib CAS# 1374743-00-6

Trilaciclib (G1T28) is a potent, selective, reversible cyclin-dependent kinase 4/6 (CDK4/6) inhibitor developed for myelopreservation. In preclinical biochemical assays, it inhibited CDK4/cyclin D1 and CDK6/cyclin D3 with IC50 values of 1 and 4 nM, respectively. In hematopoietic stem and progenitor cells, trilaciclib induced transient G1 cell-cycle arrest, protecting them from cytotoxic chemotherapy-induced damage without impairing proliferation after recovery. In mouse models, co-administration with chemotherapy preserved bone marrow function, reduced myelosuppression, and improved survival. Pharmacokinetic studies showed rapid distribution, short half-life, and reversible CDK4/6 inhibition. These findings supported trilaciclib’s development as a first-in-class myeloprotective agent during cancer therapy.